Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vanguard Plus 5
- Development stage
- Unknown
- Lead developer
- Zoetis
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
Vanguard Plus 5 is a multivalent veterinary vaccine developed by Zoetis (formerly Pfizer Animal Health) for the immunization of healthy dogs aged 6 weeks or older. It is a lyophilized (freeze-dried) preparation containing live attenuated strains of canine distemper (CD) virus, canine adenovirus type 2 (CAV-2), canine parainfluenza (CPI) virus, and canine parvovirus (CPV). The vaccine is specifically formulated with a high-titer, low-passage CPV strain designed to be highly immunogenic and capable of overcoming maternal antibody interference in young puppies. It provides protection against canine distemper, infectious canine hepatitis (caused by CAV-1), respiratory disease (caused by CAV-2), canine parainfluenza, and canine parvoviral enteritis (including disease caused by CPV-2c).
- Brand names
- Vanguard Plus 5
02
Targets
CPV capsid (Canine parvovirus capsid protein)PIV5 (Parainfluenza virus 5)CAdV-2 (Canine adenovirus type 2)
Beyond the preview
Go deeper on Vanguard Plus 5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vanguard Plus 5.